Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ ...

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over ...

Panelists discuss how alectinib use in the adjuvant setting might shift sequencing strategies in metastatic ALK+ non–small cell lung cancer (NSCLC) and how resistance mutations influence ...

Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple ...

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

CK Wang, MD, explains that Black women face higher rates of late-stage breast and ovarian cancer diagnoses, demonstrating the ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

An ASCO session on quality services shows how patient and caregiver engagement is crucial to gain better outcomes and cost ...

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking ...

A new State of Drug Access report shows that more than 40% of people living in the US could not afford their prescribed drugs ...